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Preservation of Cognitive Function in
Primary CNS Lymphoma Survivors a
Median of 12 Years After Enhanced
Chemotherapy Delivery
TO THE EDITOR: Since 1982, 112 patients newly diagnosed with
primary CNS lymphoma (PCNSL) have been treated at Oregon
Health and Science University with methotrexate (intra-arterial)–
based chemotherapy in conjunctionwithosmotic blood-brainbarrier
disruption (BBBD) without whole-brain irradiation. We previously
published survival outcomes associated with this first-line therapy.1,2
Pretreatment (baseline) neuropsychological and neuroimaging eval-
uation has routinely been conducted in patients with PCNSL treated
with BBBD.This correspondence summarizes recent findings regard-
ing neuropsychological and neuroimaging outcomes in 26 long-term
survivors of PCNSL treated with this therapy.
From February 2009 to February 2011, we prospectively evalu-
ated long-term survivors of PCNSL to assess changes inneuropsycho-
logical scores and the association with pretreatment and long-term
neuroimaging outcomes. Survivors who were a minimum of 2 years
post diagnosis and in complete remission after BBBD treatment
were evaluated with neuropsychological tests and brain magnetic
resonance (MR) or computed tomography (CT) imaging.3 Com-
plete disease remission was required to assess neurotoxicity with-
out the confounding presence of infiltrative, often multifocal CNS
disease. Neuropsychological scores were available on 24 of 26
long-term survivors; pretreatment scores were not available on one
of the 24 survivors.
Neuropsychological tests included in a test battery that was de-
veloped by international PCNSL investigators were used to evaluate
neurotoxicity.4 The tests measure attention/executive function
(Wechsler Adult Intelligence Scale—III Digit Span subtest [Digits
Forward, Digits Backward], Trail Making Test [TMT] A and B), and
verbal memory (Hopkins Verbal Learning Test—Revised). For neu-
roimaging, the axial section with the largest enhancing tumor was
selected on pretreatment contrast-enhanced T1-weighted MR or CT
images, and abnormal MR T2 hyperintensity or CT hypodensity
aroundenhancing tumorwasassessed in the sameplane.The increase,
decrease, or stable appearance and size of lesions at completion of
BBBD and long term were compared with pretreatment measure-
ments. Amultivariable linearmixedmodelwas used to assess changes
in neuropsychological least squares mean scores, and the association
between pretreatment and long-term outcomes was assessed using
Pearson’s correlation coefficient.
The median age at diagnosis was 50 years. Eight patients (33%)
were age 60 years or older; seven (29%) had aKarnofsky performance
score of less than 70. Themedian interval fromdiagnosis to long-term
evaluation was 12 years (minimum, 2 years; maximum, 26 years);
eight survivors (33%)were evaluated 15 years ormore after diagnosis.
There was significant improvement in TMT A (P .0085), TMT B
(P  .0411), and attention/executive function domain (P  .001)
from pretreatment to long term (Fig 1 and Appendix Figure A1A,
online only). There were no significant changes in Digits Forward,
Digits Backward, and verbal memory. The majority showed stable or
improved cognitive status at long term (Appendix Fig A1B, online
only). Before diagnosis, 17 patients were working, two were college
students, four were retired, and one was unemployed as a result of
psychomotor slowing and depression. Of the 17 who were working
and the two students, at long term, 11 had retired, six were employed
(including the students), and twowere disabled as a result of orthope-
dic problems. Of eight survivors evaluated 15 years or more after
diagnosis, five were working in high-level occupations as a surgeon,
attorney, registered nurse, law enforcement officer, and optician.
Three were retired.
On neuroimaging, the total T2 MR hyperintensities or CT hy-
podensities decreased or resolved by the end of treatment in 75% of
survivors. Total T2MR hyperintensities or CT hypodensities did not
change from the end of treatment to long term. There was no associ-
ation between neuropsychological scores and neuroimaging pretreat-
ment and long term.
With a median follow-up of 12 years, comparison of pretreat-
ment and long-term scores indicates preserved cognitive function in
the majority of survivors. We are not aware of studies that have
evaluated cognition and neuroimaging with such lengthy follow-up,
showing preserved or improved cognitive functioning in this rare
cancer. Our data showed significant improvement in TMT A and B,
which measure speed of information processing and complex set
shifting. The improvement in TMT B, which measures executive
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functioning, is likely an important component of why survivors were
able to return to high-level occupations. Nonetheless, verbal learning
and memory did not significantly improve, and some survivors had
long-term cognitive limitations. This reinforces the importance of
identifying rehabilitation strategies for survivors with residual cogni-
tive deficits.
The importanceofprospectivepretreatment and long-termeval-
uation to understand cognitive effects of cancer treatment has been
established.5-7 However, few studies have included pre- and post-
treatment psychometric evaluation, and data regarding long-term
impact of most treatments are sparse. As PCNSL treatment regimens
intensify, whether by high-dose chemotherapywith or without autol-
ogous stem-cell transplantation, or by BBBD, durable remission rates
and survival are expected to increase. Increased survival in combina-
tion with intact cognitive abilities is widely acknowledged as a critical
benchmark for determining the optimum therapy for this disease.1-3,8
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Fig 1. Baseline and long-term cognitive outcomes. Raw test scores were con-
verted to z-scores that were based on normative values demographically adjusted to
age. A domain score was obtained by averaging all test z-scores in each domain, for
each participant. The z-score (mean  SD) across survivors at baseline (pretreat-
ment), long-term follow-up, and the change score are shown. The asterisks indicate
statistical significance. There was improvement in Trail Making A, P  .0085; Trail
Making B, P  .0411; and Attention/Executive Function domain, P  .001.
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Fig A1. (A) The z-score (mean  SD) across survivors at baseline (pretreatment), long-term follow-up, and the change score for Verbal Memory Learning, Verbal
Memory Delayed, and for Verbal Memory Domain are shown. There was no significant change from baseline to long-term follow-up. (B) Number of patients who
declined (z-score declined 1 SD or more), were stable (z-score remained within 1 SD of baseline score), and improved (z-score improved 1 SD or more) from baseline
(pretreatment) to long-term follow-up for the following tests: Digit Span Forward, Digit Span Backward, Trail Making A, Trail Making B, Verbal Memory Learning, and
Verbal Memory Delayed.
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